title: Effects of chronic toluene exposure on central monoamine and peptide receptors and their interactions in the adult male rat.
abstract: The effects of chronic toluene exposure (CTE) (80 ppm, 6 h/day, 5 days/week, 3 months) were studied on neuropeptide and 5-hydroxytryptamine receptors, on protein phosphorylation levels and on catecholamine levels in various brain regions in the 15-month-old male rat. Behavioral parameters and serum levels of hypophyseal hormones and corticosterone were also analyzed. CTE selectively reduced [3H]neurotensin [( 3H]NT) binding in the basal layers of the orbital cortex. Instead, CTE increased the binding of [3H]etorphine in the nucleus accumbens and of [125I]vasoactive intestinal polypeptide [( 125I]VIP) in the area postrema and hypoglossal nucleus. Acute treatment with the irreversible monoamine receptor antagonist N-ethoxycarboxyl-2-ethoxy-1,2-dihydroquinoline (EEDQ) increased the binding of [3H]NT in the orbital cortex in toluene exposed rats as compared with the reduced [3H]NT binding obtained in air exposed rats treated with EEDQ. Furthermore, the EEDQ induced increase in [125I]VIP binding in the area postrema and the hypoglossal nucleus was replaced by a reduced binding of [125I]VIP in EEDQ-treated CTE rats. CTE produced an overall increase in calcium-induced back phosphorylation and an overall decrease in cyclic adenosine monophosphate-induced back phosphorylation in the frontoparietal cortex. Noradrenaline stores tended to be reduced within various hypothalamic subnuclei and the serum prolactin levels were increased following CTE. However, no marked effects of CTE were seen on the behavioral parameters. In conclusion, the regional selectivity of CTE in disturbing [3H]NT and [125I]VIP binding may be due to the demonstrated vulnerability of monoamine-neuropeptide interactions to toluene.
authors.affiliation: Department of Histology and Neurobiology, Karolinska Institute, Stockholm, Sweden.
authors.forename: G
authors.initials: G
authors.lastname: von Euler
authors.forename: K
authors.initials: K
authors.lastname: Fuxe
authors.forename: T
authors.initials: T
authors.lastname: Hansson
authors.forename: S O
authors.initials: SO
authors.lastname: Ogren
authors.forename: L F
authors.initials: LF
authors.lastname: Agnati
authors.forename: P
authors.initials: P
authors.lastname: Eneroth
authors.forename: A
authors.initials: A
authors.lastname: Härfstrand
authors.forename: J A
authors.initials: JA
authors.lastname: Gustafsson
mesh_terms: D000818:Animals; D001345:Autoradiography; D001921:Brain / Q000187:drug effects* / Q000378:metabolism; D004347:Drug Interactions; D008297:Male; D009043:Motor Activity / Q000187:drug effects; D009479:Neuropeptides / Q000378:metabolism*; D010766:Phosphorylation; D011804:Quinolines / Q000494:pharmacology; D051381:Rats; D011919:Rats, Inbred Strains; D011964:Receptors, Gastrointestinal Hormone / Q000187:drug effects; D017476:Receptors, Neuropeptide Y; D018028:Receptors, Neurotensin; D017981:Receptors, Neurotransmitter / Q000187:drug effects*; D011957:Receptors, Opioid / Q000187:drug effects; D011985:Receptors, Serotonin / Q000187:drug effects*; D018005:Receptors, Vasoactive Intestinal Peptide; D014050:Toluene / Q000633:toxicity*
chemical_list: C031182:LSD receptor; D009479:Neuropeptides; D011804:Quinolines; D011964:Receptors, Gastrointestinal Hormone; D017476:Receptors, Neuropeptide Y; D018028:Receptors, Neurotensin; D017981:Receptors, Neurotransmitter; D011957:Receptors, Opioid; D011985:Receptors, Serotonin; D018005:Receptors, Vasoactive Intestinal Peptide; D014050:Toluene; C000470:EEDQ